BARCELONA, Spain--(BUSINESS WIRE)--At six months, the NEVO™ Sirolimus-eluting Coronary Stent, incorporating RES Technology™, was superior to the Taxus® Liberte® Stent in reducing tissue growth within the stent that can potentially lead to repeat procedures, in new clinical study results released today. In addition, no reports of stent thrombosis were reported in patients treated with NEVO™ through six months.
